Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.

Abstract

PURPOSE Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer. Among patients who initially respond to trastuzumab therapy, resistance typically arises within 1 year. BT/Her(R) cells are trastuzumab-resistant variants of Her2-positive BT474 breast cancer cells. The salient feature of BT… (More)
DOI: 10.1158/1078-0432.CCR-09-0585

Topics

8 Figures and Tables

Cite this paper

@article{Gu2009ProteinKA, title={Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.}, author={Long Gu and Sean Lau and Sofia Loera and George Somlo and Susan E. Kane}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2009}, volume={15 23}, pages={7196-206} }